Gilead's coronavirus drug remdesivir will cost over $3,000
Gilead Sciences, the American pharmaceutical company producing a Food and Drug Administration-approved antiviral drug being used to treat severe cases of COVID-19, had agreed to donate its supply of remdesivir through the end of June, but it's now time to put a price on the potentially game-changing medicine — and it won't be cheap.
In the United States, remdesivir will cost $520 per dose, which amounts to more than $3,000 over the course of a typical coronavirus treatment. While that's a lot of money, CNBC reports the price is actually lower than the $5,000 per course some were expecting. Gilead said remdesivir is being offered at a discount "well below value," noting the pandemic requires they do things differently.
The drug will actually be offered at a lower price outside the U.S. Per CNBC, in "other developed countries" the entire course of treatment will cost $2,340, which Gilead says is the result of the way the drug discounting system in the U.S. works.
Article continues belowThe Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
